These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 11948493)

  • 1. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma.
    Whiteman DC; Zhou XP; Cummings MC; Pavey S; Hayward NK; Eng C
    Int J Cancer; 2002 May; 99(1):63-7. PubMed ID: 11948493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
    Zhou XP; Gimm O; Hampel H; Niemann T; Walker MJ; Eng C
    Am J Pathol; 2000 Oct; 157(4):1123-8. PubMed ID: 11021816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma.
    Koenig A; Bianco SR; Fosmire S; Wojcieszyn J; Modiano JF
    Vet Pathol; 2002 Jul; 39(4):458-72. PubMed ID: 12126149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
    Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
    Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.
    Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
    Genes Chromosomes Cancer; 2002 Sep; 35(1):74-80. PubMed ID: 12203792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma.
    Tsao H; Mihm MC; Sheehan C
    J Am Acad Dermatol; 2003 Nov; 49(5):865-72. PubMed ID: 14576666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
    Marsh DJ; Coulon V; Lunetta KL; Rocca-Serra P; Dahia PL; Zheng Z; Liaw D; Caron S; Duboué B; Lin AY; Richardson AL; Bonnetblanc JM; Bressieux JM; Cabarrot-Moreau A; Chompret A; Demange L; Eeles RA; Yahanda AM; Fearon ER; Fricker JP; Gorlin RJ; Hodgson SV; Huson S; Lacombe D; Eng C
    Hum Mol Genet; 1998 Mar; 7(3):507-15. PubMed ID: 9467011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma.
    Hu TH; Huang CC; Lin PR; Chang HW; Ger LP; Lin YW; Changchien CS; Lee CM; Tai MH
    Cancer; 2003 Apr; 97(8):1929-40. PubMed ID: 12673720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of PTEN mutations in metastatic melanoma specimens.
    Celebi JT; Shendrik I; Silvers DN; Peacocke M
    J Med Genet; 2000 Sep; 37(9):653-7. PubMed ID: 10978354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors.
    Gimm O; Perren A; Weng LP; Marsh DJ; Yeh JJ; Ziebold U; Gil E; Hinze R; Delbridge L; Lees JA; Mutter GL; Robinson BG; Komminoth P; Dralle H; Eng C
    Am J Pathol; 2000 May; 156(5):1693-700. PubMed ID: 10793080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.
    Birck A; Ahrenkiel V; Zeuthen J; Hou-Jensen K; Guldberg P
    J Invest Dermatol; 2000 Feb; 114(2):277-80. PubMed ID: 10651986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated Akt3 activity promotes development of malignant melanoma.
    Stahl JM; Sharma A; Cheung M; Zimmerman M; Cheng JQ; Bosenberg MW; Kester M; Sandirasegarane L; Robertson GP
    Cancer Res; 2004 Oct; 64(19):7002-10. PubMed ID: 15466193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
    Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
    Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
    Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
    Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.
    Mikhail M; Velazquez E; Shapiro R; Berman R; Pavlick A; Sorhaindo L; Spira J; Mir C; Panageas KS; Polsky D; Osman I
    Clin Cancer Res; 2005 Jul; 11(14):5153-7. PubMed ID: 16033830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.
    Salvesen HB; Stefansson I; Kalvenes MB; Das S; Akslen LA
    Cancer; 2002 Apr; 94(8):2185-91. PubMed ID: 12001116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis.
    Eng C
    Ann N Y Acad Sci; 2002 Jun; 968():213-21. PubMed ID: 12119278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.
    Zhou XP; Loukola A; Salovaara R; Nystrom-Lahti M; Peltomäki P; de la Chapelle A; Aaltonen LA; Eng C
    Am J Pathol; 2002 Aug; 161(2):439-47. PubMed ID: 12163369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
    Tsao H; Goel V; Wu H; Yang G; Haluska FG
    J Invest Dermatol; 2004 Feb; 122(2):337-41. PubMed ID: 15009714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
    Tsao H; Zhang X; Fowlkes K; Haluska FG
    Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.